Steminent Biotherapeutics Inc. (TPEX:7729)

Market Cap	5.06B +327.2%
Revenue (ttm)	n/a
Net Income	-155.75M
EPS	-2.77
Shares Out	66.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	391,865
Average Volume	952,192
Open	77.00
Previous Close	76.00
Day's Range	74.00 - 77.80
52-Week Range	15.25 - 94.90
Beta	n/a
RSI	52.66
Earnings Date	Apr 22, 2026

About Steminent Biotherapeutics

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington’s disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7729